No Data
Disc Medicine To Launch APOLLO Post-Marketing Trial For Biopterin In Mid-2025
Disc Medicine Analyst Ratings
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $118
LifeSci Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $85
Disc Medicine Reports 'Positive' Feedback From FDA Meeting
Disc Medicine's Promising Path: Buy Rating Backed by Regulatory Milestones and Market Potential
far008 : $Vast Renewables (VSTE.US)$ has no short shares. we should see an uptick
103822628 : Sorry , unusual volume ticks means wat?
Stock_Drift OP 103822628 : Look at the volume. It’s unusual